Premium
Comparative study of amlodipine vs. cilnidipine for the prevention of hepatic ischemia‐reperfusion injury in rat model
Author(s) -
Fouda AbdelMotaal,
Youssef Amany R.,
Sharaf Eldin Osama
Publication year - 2018
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12335
Subject(s) - amlodipine , medicine , ischemia , reperfusion injury , cardiology , anesthesia , blood pressure
Ca 2+ signaling plays crucial role in ischemia and reperfusion (I/R) injury. Although blockade of L‐type Ca 2+ channels by amlodipine ( AML ) has been shown to suppress hepatic I/R injury in several animal models, information is still needed regarding the hepatoprotective effects of the dual L/N‐type Ca 2+ channel blockers, cilnidipine ( CIL ). We examined the effect of pretreatment with AML or CIL (100 μg/kg i.p.) 45 min before induction of 60 min of liver ischemia followed by reperfusion, on oxidative stress markers, liver enzymes, serum tumor necrosis factor‐α, interleukin‐1β, apoptosis markers, and nuclear factor KB after 6 and 24 h of hepatic reperfusion. Both drugs significantly ameliorated biochemical and histological markers of hepatic I/R injury, but protection with CIL was more significant at the 6‐h time point where protection with AML outlasted that of CIL . Both drugs offered significant protection against hepatic I/R damage, but the protection with CIL seemed more potent but of shorter duration than that observed with AML possibly due to the shorter half‐life of CIL .